Kamada KMDA 深 沪
等待开盘 12-19 09:30:00 美东时间
7.22
+0.200
+2.85%
华盛通- 最 高7.4471
- 今 开7.23
- 成交量 11.54万股
- 最 低 7.22
- 昨 收 7.02
- 总市值 4.16亿
- 52周最高 8.955
- 市盈率 静 28.87
- 换手率 0.00%
- 52周最低 5.54
- 委 比 52.52%
- 总股本 5768.16万
- 历史最高 17.75
- 量 比 2.10
- 振 幅 3.24%
- 历史最低 2.82
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender
Kamada ( ($IL:KMDA) ) has shared an announcement. On December 18, 2025, Kamada ...
12-18 20:27
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Kamada Reiterates its 2025 Revenue Guidance of $178M-$182M Vs. Consensus Of $180.66M, And Adjusted EBITDA of $40M-$44M
Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026
12-08 20:08
Kamada To Discontinue Phase 3 InnovAATe Trial As Prespecified Interim Futility Analysis Shows The Trial Of Inhaled AAT For Alpha-1 Antitrypsin Deficiency Is Unlikely To Demonstrate A Statistically Significant Benefit In Its Primary Endpoint
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA, its AAT-IV
12-08 20:06
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
Alvotech and Advanz Pharma announce the European Commission's approval of Gobivaz®, the first biosimilar to Simponi® (golimumab), for treating immune-mediated diseases such as rheumatoid arthritis and psoriatic arthritis. The partnership allows Alvotech to develop and supply the product, while Advanz Pharma handles registration and commercialization in the EEA and the UK. The approval follows positive opinions from the European Medicines Agency a...
11-20 09:00
Kamada Affirms FY2025 Sales Guidance of $178.000M-$182.000M vs $180.659M Est
Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000 million-$182.000 million vs $180.659 million estimate.
11-10 20:24
Kamada Q3 EPS $0.09 Misses $0.10 Estimate, Sales $47.010M Beat $45.811M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.10 by 7.22 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same
11-10 20:11
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
Alvotech has won a UK High Court decision allowing it to proceed with manufacturing its biosimilar to Eylea® (AVT06), after Regeneron and Bayer's injunction request was rejected. The ruling supports commercial launches of AVT06 in the European Economic Area, UK, and other countries post Supplementary Protection Certificates (SPCs) expiry on November 23, 2025. The court's decision affirmsthe validity of the SPC waiver system, enabling third-party ...
11-10 09:00
An Overview of Kamada's Earnings
Kamada (NASDAQ:KMDA) will release its quarterly earnings report on Monday, 2025...
11-08 02:03
